Zipalertinib plus chemotherapy improves PFS in REZILIENT-3
Phase III REZILIENT-3 reports median progression-free survival of 14.5 months with zipalertinib plus chemotherapy versus 8.5 months with chemotherapy alone in first-line EGFR exon 20 insertion mutation NSCLC, with CNS efficacy in brain metastases and manageable safety.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.